JPM upgrades LRMR
JPMorgan initiates coverage of Larimar Therapeutics with an Overweight rating, citing potential growth prospects. This may impact the stock's performance.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.